| abstract |
Compositions for affecting weight loss are disclosed, comprising a first compound and a second compound, wherein the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a receptor. 4 of melanocortin (MC4-R), compared to normal physiological conditions. Methods are also disclosed to affect weight loss, increase energy expenditure, increase satiety in an individual or suppress an individual's appetite, which includes identifying an individual in need thereof and treating the individual to antagonize opioid receptor activity. and improve activity (-MSH. |